The 15-month bull run of U.S. stock markets suffered a surprise setback in April. We believe that April’s meltdown was nothing but a bull market correction, and this time a welcome one, as Wall Street has rebounded in May.The Department of Labor reported that the U.S. economy added 175,000 jobs in April, missing the consensus estimate of 200,000. Job additions in March were revised upward by 12,000 while those in February were revised downward by 34,000. The unemployment rate increased to 3.9% in April, com ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adma Biologics (ADMA) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Adma Biologics is a member of the Medical sector. This group includes 1048 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank considers 1 ...

财务数据和关键指标变化 - 总收入同比增长44%至81.9百万美元 [1][2][3] - 毛利润同比增长137%至39.1百万美元,毛利率约48% [3][4] - 调整后EBITDA同比增长970%至26.4百万美元 [3][4] - GAAP净利润为17.8百万美元,去年同期为净亏损6.8百万美元 [3][4] - 预计2024年和2025年收入将超过355百万美元和410百万美元,调整后EBITDA将超过110百万美元和160百万美元,净利润将超过85百万美元和135百万美元 [3][4] 各条业务线数据和关键指标变化 - 公司的主要产品Asceniv和Bivigam销售持续增长,深化在美国免疫球蛋白市场的地位 [3][4][5] - 公司专注于免疫缺陷患者群体,特别是合并其他疾病的复杂患者,这一策略帮助产品差异化并获得市场认可 [3][4][5] 各个市场数据和关键指标变化 - 公司的十家自有血浆采集中心表现良好,能够满足公司免疫球蛋白产品的生产需求 [3][5][6] - 公司正在采取措施提高高免疫力血浆的采集,如提高捐献频率和奖励等,以满足产品需求 [6][7][8] 公司战略和发展方向及行业竞争 - 公司正在通过提高生产工艺的创新来提高免疫球蛋白的产量,预计从明年下半年开始可能带来收益增长 [3][5] - 公司的高免疫球蛋白项目针对肺炎链球菌,符合未满足的医疗需求,并利用公司在临床开发、特种生物制品制造和商业产品推广方面的专长 [3][5] - 公司正在扩大人工智能和机器学习平台的应用,以优化和简化生产流程,提高运营效率 [3][5][6] - 公司认为自身在特种生物制品市场的地位独特,尚未发现有竞争对手能够生产类似的高免疫球蛋白产品 [7][8][9] 管理层对经营环境和未来前景的评论 - 管理层对公司未来的收入和利润增长前景充满信心,并大幅上调了2024年和2025年的财务指引 [3][4][5] - 管理层认为公司有望在2025年之后实现更高的收入和利润增长,但需要等待进一步的内部项目进展和生产工艺改进 [9][10] - 管理层表示将继续关注股东回报,包括考虑股票回购等方式来提升股东价值 [6][7] 问答环节重要的提问和回答 问题1 **Anthony Petrone提问** 询问公司当前的产能利用率以及未来的收入增长潜力 [5][6] **Adam Grossman回答** - 公司当前的产能利用率在70%-80%左右,未来有进一步提升的空间 - 公司认为未来收入增长潜力巨大,可能在410百万美元到20亿美元之间 - 公司正在采取措施提高高免疫力血浆的采集,以满足产品需求 [6][7][8] 问题2 **Kristen Kluska提问** 询问公司是否考虑利用现金流进行再投资或股票回购等 [6][7] **Brian Lenz回答** - 公司将密切关注现金流情况,考虑适当时机进行债务偿还或股票回购等方式提升股东价值 - 公司也将投资于数据分析、IT基础设施等方面,以提高运营效率和盈利能力 [6][7][8] 问题3 **Gary Nachman提问** 询问公司对2025年以后的业务前景展望及分析 [9][10] **Adam Grossman回答** - 公司对2025年以后的收入和利润增长前景充满信心,但需要等待进一步的内部项目进展和生产工艺改进 - 公司将在适当时机提供更多定量的财务预测和分析,目前主要关注近期的高速增长 [9][10]

Adma Biologics (ADMA) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 60%. A quarter ago, it was expected that this infectious disease drug developer would post earnings of $0.02 per share when it actually produced earnings of $0.04, delivering a surprise of 100%.Over the last four quarte ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36728 ADMA BIOLOGICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2590442 (State o ...

Exhibit 99.1 ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update 1Q 2024 Total Revenue of $81.9 Million, a 44% Increase Y-o-Y 1Q 2024 GAAP Net Income of $17.8 Million, a $24.6 Million Increase Y-o-Y 1Q 2024 Adjusted EBITDA(1) of $26.4 Million, a 970% Increase Y-o-Y FY 2024 and 2025 Total Revenue Guidance Increased to More Than $355 Million and $410 Million, Respectively FY 2024 Net Income Guidance Increased to More Than $85 Million and Adjusted EBITDA Guidance Increase ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Adma Biologics (ADMA) .Adma Biologics currently has an average brokerage r ...

We expect investors to focus on the sales performance of ADMA Biologics, Inc.’s (ADMA) portfolio of its three marketed commercial products and other pipeline updates when it reports first-quarter 2024 results.Let’s see how things have shaped up for the quarter to be reported.Factors at PlayADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases. The company’s top line currently comprises sales of three FDA-approved products, ...

tazytaz/E+ via Getty Images Today, we are going to do something different to close out another trading week. In this column, I highlight three biotech stocks with favorable risk/reward profiles and that are trading for under ten bucks a share. Let's start with ADMA Biologics, Inc. (ADMA). This company is focused on manufacturing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. ADMA Biologics recently brought online the last of 10 large plasma collection fa ...

股票趋势分析 - 短期投资或交易中，趋势是最赚钱的策略之一[1] - 为了从趋势中获利，需要确保趋势的可持续性，这并不容易[1] - 通过“最近价格强势”筛选，可以找到具有足够基本面强势的股票，这有助于维持股票的上涨趋势[3] - ADMA Biologics (ADMA)是通过筛选的股票之一，具有投资“趋势”的潜力[4] - ADMA在过去12周内股价上涨了22.2%，显示投资者愿意为其潜在上涨支付更多[5] - 过去四周股价上涨了0.6%，表明股价趋势仍在持续[6] - ADMA目前交易在其52周高低范围的94.1%，暗示可能即将突破[7] - ADMA的平均经纪人推荐为1（强烈买入），表明经纪界对其近期股价表现持乐观态度[9] - ADMA的价格趋势可能不会很快逆转[9] 潜在投资机会 - 除了ADMA，还有其他股票通过了“最近价格强势”筛选，值得考虑投资[10]